A retrospective survey «Rasmussen A, Brandi S, Fuchs J ym. Visual outcomes...»1 was conducted in Denmark, in order to study the relation between the interval from diagnosis to initiation of intravitreal anti-VEGF injection therapy and visual outcome in neovascular age-related macular degeneration (nAMD). The study included 1185 eyes in 1099 patients who began ranibizumab treatment for nAMD during four separate periods in 2007, 2009, 2001 and 2012. The best-corrected visual acuity (BCVA) at the diagnosis remained within the range 0.23–0.24 Snellen and the median patient age within 79–80 years. The median time from diagnosis to treatment was 16 days in 2007, 11 days in 2009, 2 days in 2011 and 1 day in 2012. Simultaneously, BCVA at first visit after the third monthly injection increased from 0.24 to 0.31 Snellen (p<0.0001) in concert with a shift in preferred practice from separate-day injection to same-day injection. Also the mean number of letters gained increased (2.6 in 2007, 0.4 in 2009, 5.3 in 2011 and 6.3 in 2012).